ArticleNucleic acids research2026
RM2Target v2.0: an updated database for the target genes of writers, erasers, and readers of RNA modifications.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes.iMeta · 2026Review
- A functional map of mNature cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Defining regulatory associations between RNA modification proteins [writers, erasers, and readers (WERs)] and their target genes is crucial for elucidating the molecular mechanisms underlying RNA modifications. We previously developed RM2Target, a comprehensive database of WER-target associations across nine RNA modification types in humans and mice, which has become a widely utilized resource in the field. However, the growing body of research on novel RNA modifications and non-model species has created an urgent need for a significant expansion of the database. Here, we introduce RM2Target v2.0 (http://rm2target.canceromics.org/), an updated version featuring substantially expanded data coverage and enhanced curation. The new release includes 4 400 616 WER-target associations, encompassing 273 WER proteins from 18 RNA modification types and spanning 973 cell lines or tissues across 20 species. Additionally, RM2Target v2.0 provides extensive annotations for target genes, including basic gene information, associated RNA modifications, RNA-RNA and RNA-protein interactions, and disease linkages. We expect that RM2Target v2.0 will serve as a foundational resource for exploring RNA epitranscriptomic regulation, enabling investigations into cross-talk among modifications, underlying molecular mechanisms, and disease connections, thereby facilitating both basic research and translational applications in RNA epigenetics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.